Business Context and Reporting Period
This Form 8-K Current Report was filed by Absci Corporation on July 7, 2025. The filing discloses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
- Board Appointment: Mary Szela was appointed to the Board of Directors effective July 7, 2025.
- Board Composition: The Board size was fixed at seven directors, adding a third director position to Class III.
- Director Tenure: Ms. Szela will serve until the 2027 annual meeting of stockholders or until earlier resignation, death, or removal.
Compensation and Governance Details
- Equity Grant: Ms. Szela received an initial option to purchase 178,400 shares of common stock at the closing market price on the grant date.
- Vesting Schedule: The option vests in equal monthly installments over three years, contingent on continued service. Full vesting occurs upon a "Sale Event."
- Cash Compensation: An annual cash retainer of $40,000 was approved for her services.
- Background: Ms. Szela currently serves as CEO, President, and Director of Trisalus Life Sciences.
Investor Verification Checklist
- Verify the closing market price of ABSI stock on July 7, 2025, to determine the exercise price of the 178,400 share option grant.
- Review the Company's 2021 Stock Option and Incentive Plan for the specific definition of a "Sale Event" triggering accelerated vesting.
- Confirm the total number of outstanding shares and the dilution impact of the new option grant.
- Assess the strategic value of Ms. Szela's experience at Trisalus Life Sciences relative to Absci's current business objectives.